12 Covid-19 vaccines to watch

A range of Covid-19 vaccines are being developed worldwide. Which ones are authorised and assessed in the EU? Which are still in development? Check our table below.

Company Type Efficacy* Doses Storage Status in Europe* Secured by EU

Pfizer / BioNTech ๐Ÿ‡ฉ๐Ÿ‡ช๐Ÿ‡บ๐Ÿ‡ธ

ย 
mRNA*

95%

ย 

๐Ÿ’‰๐Ÿ’‰
(๐Ÿ’‰)

ย 
2.4 bn
Moderna ๐Ÿ‡บ๐Ÿ‡ธ
mRNA

94.1%

ย 

๐Ÿ’‰๐Ÿ’‰
(๐Ÿ’‰)

ย 
-20ยฐC
460 mn
AstraZeneca / Oxford ๐Ÿ‡ธ๐Ÿ‡ช๐Ÿ‡ฌ๐Ÿ‡ง
Adenovirus-vectored technology*

60% - 82%

ย 
๐Ÿ’‰๐Ÿ’‰
Fridge
400 mn
Johnson&Johnson / Janssen ๐Ÿ‡ง๐Ÿ‡ช๐Ÿ‡บ๐Ÿ‡ธ
Adenovirus-vectored technology

67%

ย 
๐Ÿ’‰
Fridge
400 mn
Novavax ๐Ÿ‡ธ๐Ÿ‡ช๐Ÿ‡บ๐Ÿ‡ธ
Protein

89.3%

ย 
๐Ÿ’‰๐Ÿ’‰
Fridge
~200 mn
CVnCoV - CureVac AG ๐Ÿ‡ฉ๐Ÿ‡ช
mRNA
โ”
๐Ÿ’‰๐Ÿ’‰
Fridge
405 mn
Sputnik V - Gamaleya Research Institute ๐Ÿ‡ท๐Ÿ‡บ
Adenovirus-vectored technology

91.6%

ย 
๐Ÿ’‰๐Ÿ’‰
-18ยฐC

Rolling review
Emergency use in Hungary, BiH, Serbia, Montenegro

ย 
CoronaVac - Sinovac ๐Ÿ‡จ๐Ÿ‡ณ
Inactivated virus
๐Ÿ’‰๐Ÿ’‰
Fridge

Rolling review
Emergency use in Turkey

ย 
BBIBP-CorV - Sinopharm ๐Ÿ‡จ๐Ÿ‡ณ
Inactivated virus
๐Ÿ’‰๐Ÿ’‰
Fridge
Emergency use in Hungary, Serbia
VLA2001 - Valneva ๐Ÿ‡ซ๐Ÿ‡ท
Inactivated virus
โ”
โ”
Fridge

In development

ย 
~60 mn
mRNA & protein
โ”
โ”
โ”

Rolling review of Vidprevtyn
(protein-based vaccine)

ย 
300 mn

โ€ข Efficacy: numbers vary in different sources
โ€ข mRNA: messenger RNA, part of the virusโ€™ genetic code
โ€ข Adenovirus-vectored technology: genetically modified cold virus
โ€ข Status in Europe: overview of the situation in EU and in the candidates/potential candidates countries.

Sources: WHO, EMA, EC, Astrazeneca, Sanofi, JnJ, Novavax, SputnikVaccine, TheLancet, Nature & other.

Last update : 26 October 2021

ย